TerrAscend Corp. (TSNDF) demonstrated strong financial performance in Q1 2026, achieving a net revenue of $65.5 million and a gross profit margin of 52.8%. The recent shift to Schedule III for medical cannabis is expected to enhance profits and growth prospects, particularly with anticipated adult-use legalization, paving the way for access to institutional capital.
TerrAscend’s positive financial results coupled with regulatory advancements, such as the rescheduling of medical cannabis, support a bullish outlook given the potential for improved earnings and market access.
Consider initiating a long position in TSNDF as regulatory shifts support growth, targeting a 3-6 month horizon for price appreciation.
This news fits under 'Corporate Developments' due to financial results revealing operational advancements and potential growth aligned with regulatory changes, increasing investor interest in TSNDF’s performance.